William Blair Has Negative Outlook of NMRA FY2024 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Stock analysts at William Blair decreased their FY2024 earnings estimates for Neumora Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($1.48). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Several other equities research analysts have also recently issued reports on NMRA. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.67.

Neumora Therapeutics Stock Performance

NMRA opened at $10.84 on Friday. The company’s 50-day simple moving average is $13.09 and its two-hundred day simple moving average is $11.41. Neumora Therapeutics has a 52-week low of $8.33 and a 52-week high of $21.00. The stock has a market capitalization of $1.75 billion, a P/E ratio of -5.84 and a beta of 3.92.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07). During the same period last year, the company earned ($1.14) earnings per share.

Insider Transactions at Neumora Therapeutics

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now owns 154,658 shares of the company’s stock, valued at approximately $1,821,871.24. This trade represents a 16.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,538 shares of company stock worth $1,390,513. 26.40% of the stock is currently owned by insiders.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Artal Group S.A. raised its position in shares of Neumora Therapeutics by 14.5% in the 1st quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock worth $40,206,000 after acquiring an additional 371,350 shares in the last quarter. State Street Corp grew its stake in Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after purchasing an additional 707,409 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Neumora Therapeutics in the first quarter worth about $10,354,000. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after buying an additional 406,891 shares during the last quarter. Finally, Callan Capital LLC boosted its holdings in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after buying an additional 456,207 shares in the last quarter. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.